Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

349.92 -1.56 (-0.44%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Anthropic Is Worth $380 Billion: This Little-Known ETF Could Let You Own a Piece Before It IPOs ↗

March 19, 2026

Anthropic recently closed a $30 billion Series G funding round valuing the company at $380 billion.

Via The Motley Fool

Topics Artificial Intelligence ETFs

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report ↗

March 16, 2026

Amgen Inc. (NASDAQ: AMGN) and GSK plc (NYSE: GSK) are reportedly set to announce their partnership with TrumpRx.gov. This collaboration is set to offer substantial discounts on prescription drugs.

Via Benzinga

Amgen CEO Teases 2026 As ‘Springboard Year’ After 14 Blockbusters And 18 Record Products ↗

February 04, 2026

Via Stocktwits

1 ETF That Could Turn $100 Per Month Into $67,380 ↗

March 15, 2026

How does solid growth -- plus a 3.3% dividend yield sound?

Via The Motley Fool

Topics ETFs Economy World Trade

2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

March 13, 2026

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that mos...

Via StockStory

Topics Energy

Rapid Micro (RPID) Earnings Call Transcript ↗

March 12, 2026

Rapid Micro (RPID) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

March 08, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ:AMGN) and its p...

Via StockStory

Topics Artificial Intelligence

Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗

March 08, 2026

They may appeal to different kinds of investors.

Via The Motley Fool

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

Via Stocktwits

Topics Artificial Intelligence

2 Profitable Stocks with Solid Fundamentals and 1 Facing Headwinds

March 02, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

A Couple's Financial Manifesto, Revisited ↗

March 02, 2026

There's nothing more romantic than talking about money with your partner. Right?

Via The Motley Fool

Topics Stocks

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

February 27, 2026

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Via Finterra

Topics Economy Intellectual Property

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Via MarketMinute

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Via MarketMinute

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Via MarketMinute

Topics Earnings

February 22, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can...

Via StockStory

1 Momentum Stock to Research Further and 2 We Avoid

February 18, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Topics Earnings Economy

Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation

February 13, 2026

As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...

Via MarketMinute

Topics Artificial Intelligence ETFs Government

1 Large-Cap Stock Worth Your Attention and 2 We Avoid

February 12, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call

February 10, 2026

Amgen’s fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire. CEO...

Via StockStory

Topics Earnings

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗

February 05, 2026

The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes...

Via Stocktwits

Topics Economy Government World Trade

Healthcare Titans Propel Dow to Record Highs as GLP-1 Sales Spark Major Market Rotation

February 05, 2026

As the first week of February 2026 unfolds, a dramatic shift in investor sentiment has split the U.S. stock market. While technology and artificial intelligence stocks have faced a sharp pullback, the...

Via MarketMinute

Topics Artificial Intelligence Earnings Intellectual Property

These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? ↗

February 05, 2026

Wegovy might be getting more competition soon.

Via The Motley Fool

Topics Intellectual Property

The $1 Trillion Apothecary: A Deep-Dive Research Report on Eli Lilly (LLY)

February 05, 2026

As of February 5, 2026, Eli Lilly and Company (NYSE: LLY) stands as a paradigm-shifting titan in the global healthcare landscape. Having recently crossed the historic $1 trillion market capitalization...

Via Finterra

Topics Earnings Economy Intellectual Property

Why Is Amgen Stock Falling Premarket? ↗

February 05, 2026

Wall Street’s updated price targets on Amgen imply a wide range from about 16% downside to a 15% upside from the stock’s last close.

Via Stocktwits

Explore the top gainers and losers within the S&P500 index in today's session. ↗

February 04, 2026

Via Chartmill

Wednesday's session: top gainers and losers in the S&P500 index ↗

February 04, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.